Influenza Array to Study Genetic Drift of H1N1 Swine Flu
|
By LabMedica International staff writers Posted on 12 Nov 2009 |
|
A U.S. Army medical center is using a new influenza detection system to analyze influenza cases, including those involving H1N1 swine flu.
CombiMatrix Corp. (Mukilteo, WA, USA) announced that Brooke Army Medical Center (BAMC; San Antonio, CA, USA) is using the CombiMatrix influenza detection array. Brooke Army Medical Center (BAMC; San Antonio, TX, USA) is a military hospital that is investigating the feasibility of screening all patients presenting in its emergency room with symptoms of respiratory distress and consenting to nasal swabs, by both electrochemical array-based diagnostics and bead-based multiplex fluorescent methods.
While there are other flu tests including the fluorescent test used at BAMC that can identify the presence or absence of H1N1 swine flu, they do not provide information on genetic drift of the virus. It is important to understand the genetic drift of rapidly mutating pathogens in general and of swine flu in particular because of the potential for increased pathogenicity of a mutated virus.
Worldwide, there are already several hundred thousand confirmed cases, and the World Health Organization (Geneva, Switzerland) has declared a pandemic. Although some of these estimates might be high, the numbers distinctly indicate that this viral disease is a major public health concern. Because swine flu can be a rapidly mutating virus, concerns exist about mutations that might make it more pathogenic while maintaining its highly infectious nature.
"We are pleased to be working with BAMC to evaluate the genetic drift of the swine flu virus,” stated Dr. Amit Kumar, president and CEO of CombiMatrix. "Our influenza array has demonstrated its ability to provide tremendous genetic information regarding numerous infectious agents including bird flu, swine flu, and other infectious agents. It is especially significant to note that our influenza detection system was developed with funding from the U.S. Department of Defense, and it is now being used to evaluate infections in military, former-military, and government personnel. Also, we encourage interested parties to review information on the website of the U.S. Centers for Disease
Control and Prevention [CDC; Atlanta, GA, USA] to get an understanding of the limitations of currently available flu tests, especially what we feel is poor performance of many rapid flu tests,” concluded Dr Kumar. The link for this information is as follows given below.
According to Dr. Gerald Merrill, laboratory director for the department of clinical investigation at BAMC, "We are already seeing a high percentage of novel H1N1 flu cases in the San Antonio military community this season. The CombiMatrix system allows us to screen for Swine flu versus seasonal influenza A and influenza B. Samples analyzed using the CombiMatrix system from last season allowed us to look at clustering of genotypes and to see patterns suggesting genetic drift in both the novel H1N1 swine flu virus and the seasonal influenza A virus in San Antonio. This can be useful in spotting divergence of strains and possibly, in identifying problems earlier than if we did not screen for such divergence,” concluded Dr. Merrill.
CombiMatrix is a biotechnology business that develops proprietary technologies, including products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology, and defense and homeland security markets, as well as in other potential markets where our products and services could be utilized. The technologies the company has developed include a platform technology to rapidly produce user-defined, in situ synthesized, oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations, and proteins. This technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences, and nanotechnology. Other technologies include proprietary molecular synthesis and screening methods for the discovery of potential new drugs.
Related Links:
CombiMatrix
CDC Guidance for Diagnostic tests
CombiMatrix Corp. (Mukilteo, WA, USA) announced that Brooke Army Medical Center (BAMC; San Antonio, CA, USA) is using the CombiMatrix influenza detection array. Brooke Army Medical Center (BAMC; San Antonio, TX, USA) is a military hospital that is investigating the feasibility of screening all patients presenting in its emergency room with symptoms of respiratory distress and consenting to nasal swabs, by both electrochemical array-based diagnostics and bead-based multiplex fluorescent methods.
While there are other flu tests including the fluorescent test used at BAMC that can identify the presence or absence of H1N1 swine flu, they do not provide information on genetic drift of the virus. It is important to understand the genetic drift of rapidly mutating pathogens in general and of swine flu in particular because of the potential for increased pathogenicity of a mutated virus.
Worldwide, there are already several hundred thousand confirmed cases, and the World Health Organization (Geneva, Switzerland) has declared a pandemic. Although some of these estimates might be high, the numbers distinctly indicate that this viral disease is a major public health concern. Because swine flu can be a rapidly mutating virus, concerns exist about mutations that might make it more pathogenic while maintaining its highly infectious nature.
"We are pleased to be working with BAMC to evaluate the genetic drift of the swine flu virus,” stated Dr. Amit Kumar, president and CEO of CombiMatrix. "Our influenza array has demonstrated its ability to provide tremendous genetic information regarding numerous infectious agents including bird flu, swine flu, and other infectious agents. It is especially significant to note that our influenza detection system was developed with funding from the U.S. Department of Defense, and it is now being used to evaluate infections in military, former-military, and government personnel. Also, we encourage interested parties to review information on the website of the U.S. Centers for Disease
Control and Prevention [CDC; Atlanta, GA, USA] to get an understanding of the limitations of currently available flu tests, especially what we feel is poor performance of many rapid flu tests,” concluded Dr Kumar. The link for this information is as follows given below.
According to Dr. Gerald Merrill, laboratory director for the department of clinical investigation at BAMC, "We are already seeing a high percentage of novel H1N1 flu cases in the San Antonio military community this season. The CombiMatrix system allows us to screen for Swine flu versus seasonal influenza A and influenza B. Samples analyzed using the CombiMatrix system from last season allowed us to look at clustering of genotypes and to see patterns suggesting genetic drift in both the novel H1N1 swine flu virus and the seasonal influenza A virus in San Antonio. This can be useful in spotting divergence of strains and possibly, in identifying problems earlier than if we did not screen for such divergence,” concluded Dr. Merrill.
CombiMatrix is a biotechnology business that develops proprietary technologies, including products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology, and defense and homeland security markets, as well as in other potential markets where our products and services could be utilized. The technologies the company has developed include a platform technology to rapidly produce user-defined, in situ synthesized, oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations, and proteins. This technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences, and nanotechnology. Other technologies include proprietary molecular synthesis and screening methods for the discovery of potential new drugs.
Related Links:
CombiMatrix
CDC Guidance for Diagnostic tests
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Rapid Sepsis Test
SeptiCyte RAPID
Latest Molecular Diagnostics News
- CSF Sequencing Test Aligns with Updated Brain Tumor Guidelines
- Framework Outlines Genomic Testing Strategy for Safer Drug Dosing in Africa
- Point-of-Care PCR Panel Delivers Vaginitis Results in 20 Minutes
- Blood Test Reveals Hidden Pancreatic Cancer After Treatment
- Gene Expression Test Refines Melanoma Biopsy Decision-Making
- Genomic Assays Predict Anthracycline Benefit in Early-Stage Breast Cancer
- Ultrasensitive ctDNA Assay Detects MRD in Breast, Colorectal, Renal Cancers
- Model Predicts Increased ALS Clinic Visits with Expanded Genetic Testing
- Genetic Marker Supports Anti-TNF Therapy Selection in Crohn’s Disease
- Female-Specific RNA Biomarker May Help Explain Sex Differences in Immune Disease
- Genomic Test Guides Taxane-Based Chemotherapy Selection in Breast Cancer
- RNA Blood Test May Enable Earlier Alzheimer’s Disease Diagnosis
- AI Reasoning Model Generates Diagnostic Leads for Unresolved Rare Disease Cases
- Point-of-Care Molecular Test Detects Group A Strep in Minutes
- Spatial Map Guides Treatment Selection in Muscle-Invasive Bladder Cancer
- Point-of-Care PCR Panel Detects RSV, Influenza, and SARS-CoV-2 in Minutes
Channels
Clinical Chemistry
view channel
FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis
Chronic liver disease contributes substantially to mortality, and clinicians routinely screen adults with compensated cirrhosis for varices to prevent bleeding. However, endoscopy is invasive and reso... Read more
Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
Confirming pediatric inflammatory bowel disease (IBD) often requires imaging, endoscopy, and histopathology, prolonging time to diagnosis. Reliable, noninvasive blood tests remain an unmet need in routine... Read more
Hematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read more
Immunology
view channel
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read more
Microbiology
view channel
H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read more
Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
Colorectal cancer has been repeatedly linked to alterations in the gut microbiome, yet findings have often varied across small, heterogeneous studies. Reproducibility has been limited by differing sequencing... Read more
Pathology
view channel
AI Pathology Tool Predicts Immunotherapy Response in Rare Cancers
Immunotherapy has transformed care for select malignancies, yet predicting which patients with rare cancers are most likely to benefit remains challenging. Clinicians often have only limited biomarkers... Read more
Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
Reliable histologic subtyping guides therapy selection in oncology, yet diagnostic workflows grow more complex as whole-slide imaging and artificial intelligence (AI) expand. A persistent obstacle to clinical... Read more
Technology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read more
Industry
view channel
Partnership Integrates Automated DNA Extraction with Single-Molecule Digital PCR
Countable Labs (Palo Alto, CA, USA) and Promega (Madison, WI, USA) have entered a co-marketing agreement that integrates the Promega Maxwell System for nucleic acid extraction with Countable Labs’ Countable... Read more
